Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 512

1.

Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.

Alzahrani AS, AlQaraawi A, Al Sohaibani F, Almanea H, Abalkhail H.

Thyroid. 2012 May;22(5):536-41. doi: 10.1089/thy.2011.0247. Epub 2012 Mar 21.

PMID:
22435913
2.

Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.

Li J, Liang J, Zhao T, Lin Y.

Eur J Nucl Med Mol Imaging. 2016 Jun;43(6):1034-9. doi: 10.1007/s00259-015-3305-1. Epub 2016 Jan 16.

PMID:
26780618
3.

Distant, solitary skeletal muscle metastasis in recurrent papillary thyroid carcinoma.

Bae SY, Lee SK, Koo MY, Hur SM, Choi MY, Cho DH, Choe JH, Kim JH, Kim JS.

Thyroid. 2011 Sep;21(9):1027-31. doi: 10.1089/thy.2010.0249. Epub 2011 Aug 11.

PMID:
21834676
4.

Treatment with sorafenib in advanced thyroid cancer - a case report.

Krajewska J, Olczyk T, Roskosz J, Paliczk-Cieślik E, Smietana AK, Kaczmarek-Borowska B, Jarząb B.

Endokrynol Pol. 2010 Sep-Oct;61(5):492-6.

PMID:
21049464
5.

Pancreas as delayed site of metastasis from papillary thyroid carcinoma.

Tunio MA, Alasiri M, Riaz K, Alshakweer W.

Case Rep Gastrointest Med. 2013;2013:386263. doi: 10.1155/2013/386263. Epub 2013 Mar 27.

6.

Diagnosis and treatment of pancreatic metastases of a papillary thyroid carcinoma.

Borschitz T, Eichhorn W, Fottner C, Hansen T, Schad A, Schadmand-Fischer S, Weber MM, Schreckenberger M, Lang H, Musholt TJ.

Thyroid. 2010 Jan;20(1):93-8. doi: 10.1089/thy.2009.0026.

7.

Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation.

Iyer P, Mayer JL, Ewig JM.

Thyroid. 2014 Jan;24(1):169-74. doi: 10.1089/thy.2012.0468. Epub 2013 Jul 25.

PMID:
23544852
8.

Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).

Nucera C, Goldfarb M, Hodin R, Parangi S.

Biochim Biophys Acta. 2009 Apr;1795(2):152-61. doi: 10.1016/j.bbcan.2009.01.003. Epub 2009 Jan 31. Review.

9.

PANCREAS METASTASES FROM PAPILLARY THYROID CARCINOMA: A REVIEW OF THE LITERATURE.

Davidson M, Olsen RJ, Ewton AA, Robbins RJ.

Endocr Pract. 2017 Dec;23(12):1425-1429. doi: 10.4158/EP-2017-0001. Epub 2017 Nov 16.

PMID:
29144798
10.

The successful use of sorafenib to treat pediatric papillary thyroid carcinoma.

Waguespack SG, Sherman SI, Williams MD, Clayman GL, Herzog CE.

Thyroid. 2009 Apr;19(4):407-12. doi: 10.1089/thy.2008.0429.

PMID:
19355831
11.

Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.

Henderson YC, Ahn SH, Kang Y, Clayman GL.

Clin Cancer Res. 2008 Aug 1;14(15):4908-4914. doi: 10.1158/1078-0432.CCR-07-1772.

12.

Euthyroid status after total thyroidectomy due to functioning lung metastases from a clear cell variant of papillary thyroid carcinoma.

Lee JI, Chung YJ, Park SJ, Ryu HS, Cho BY.

Thyroid. 2012 Oct;22(10):1084-7. doi: 10.1089/thy.2011.0437. Epub 2012 Aug 8.

PMID:
22873179
13.

Associations of the BRAF(V600E) mutation with sonographic features and clinicopathologic characteristics in a large population with conventional papillary thyroid carcinoma.

Park AY, Son EJ, Kim JA, Youk JH, Park YJ, Park CS, Chang HS.

PLoS One. 2014 Oct 22;9(10):e110868. doi: 10.1371/journal.pone.0110868. eCollection 2014.

14.

Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas.

Erickson LA, Jin L, Nakamura N, Bridges AG, Markovic SN, Lloyd RV.

Cancer. 2007 May 15;109(10):1965-71.

15.

BRAFV600E mutation associated with non-radioiodine-avid status in distant metastatic papillary thyroid carcinoma.

Yang K, Wang H, Liang Z, Liang J, Li F, Lin Y.

Clin Nucl Med. 2014 Aug;39(8):675-9. doi: 10.1097/RLU.0000000000000498.

PMID:
24978326
16.

Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.

Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL.

J Clin Endocrinol Metab. 2010 Jun;95(6):2588-95. doi: 10.1210/jc.2009-1923. Epub 2010 Apr 14.

PMID:
20392874
17.

The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.

Daliri M, Abbaszadegan MR, Bahar MM, Arabi A, Yadollahi M, Ghafari A, Taghehchian N, Zakavi SR.

Endocr Res. 2014;39(4):189-93. doi: 10.3109/07435800.2013.879169. Epub 2014 Mar 28.

PMID:
24679337
18.

The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma.

Pelizzo MR, Dobrinja C, Casal Ide E, Zane M, Lora O, Toniato A, Mian C, Barollo S, Izuzquiza M, Guerrini J, De Manzini N, Merante Boschin I, Rubello D.

Biomed Pharmacother. 2014 May;68(4):413-7. doi: 10.1016/j.biopha.2014.03.008. Epub 2014 Mar 18.

PMID:
24721322
19.

The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.

Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK.

Clin Endocrinol (Oxf). 2006 Sep;65(3):364-8.

PMID:
16918957
20.

Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer.

Yoon S, An YS, Lee SJ, So EY, Kim JH, Chung YS, Yoon JK.

Medicine (Baltimore). 2015 Dec;94(48):e2063. doi: 10.1097/MD.0000000000002063.

Supplemental Content

Support Center